Advances in sequencing technology are unlocking the cancer genome and driving the explosion of a new genomic era of cancer drugs and diagnostics. With inexpensive sequencing and analysis encouraging innovation in the field, the next hurdle to overcome lies within translating this into the clinic.
The Cancer Genome Summit is the only meeting which brings together thought leaders from pharma, academia and the clinic to present the very latest clinical data. Sharing these insights holds the key to accessing the cancer genome. This year’s meeting will show you how to identify new drug targets, combat resistance mechanisms, streamline clinical trials and improve clinical management.
Imagine yourself in a room full with the leading pharma, biotech and academic organizations all speaking about how they are harnessing the cancer genome to revolutionize their drug development programs and patient treatment choice.
The Cancer Genome Summit has been specifically designed to focus on bridging the gap between sequencing the cancer genome in the lab, and our ability to use this information to develop better drugs and diagnostic technology. This meeting is designed for:
"Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues….” Director, Oncology Business Opportunities, Sanofi Aventis
“An eye-opening and extremely valuable experience, especially for those new to the field.” Novartis Molecular Diagnostics
“It exceeded my expectations. The talks were high quality and the interaction among participants was excellent.” Genentech
“A great place to get latest information and networking.” Pfizer
“Successful in bringing together pharma and diagnostics for information sharing, discussion and networking. Very informative, good representation, great networking.” Abbott Molecular
“Very valuable, well organized, good diversity of speakers.” Daiichi-Sankyo